Pulmonary arterial hypertension in the pediatric age

Journal of Cardiovascular Medicine

Volumn 8, Issue 1, 2007, Pages 72-77

  Donti, Andrea ^a   Formigari, Roberto ^a   Ragni, Luca ^a   Manes, Alessandra ^a   Galiè, Nazzareno ^a   Picchio, Fernando M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Pediatric cardiology; Pediatric diagnostic catheterization; Pulmonary hypertension

Indexed keywords

BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; UNIPROST; WARFARIN;

ANEMIA; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; EISENMENGER COMPLEX; FLUID RETENTION; HEART ATRIUM SEPTUM; HEART FAILURE; HEMANGIOMATOSIS; HEMODYNAMICS; HUMAN; INJECTION SITE PAIN; LIVER CELL DAMAGE; LUNG ARTERY PRESSURE; LUNG DYSPLASIA; LUNG TRANSPLANTATION; LUNG VEIN OBSTRUCTION; MEDICAL ASSESSMENT; MORTALITY; PATHOGENESIS; PEDIATRICS; PERIPHERAL EDEMA; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SURVIVAL; SURVIVAL RATE;

ANTIHYPERTENSIVE AGENTS; BALLOON DILATION; BRONCHOPULMONARY DYSPLASIA; CHILD; EISENMENGER COMPLEX; HEMANGIOMA, CAPILLARY; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; LUNG NEOPLASMS; LUNG TRANSPLANTATION; PERSISTENT FETAL CIRCULATION SYNDROME; PHOSPHODIESTERASE INHIBITORS; PULMONARY VENO-OCCLUSIVE DISEASE; RECEPTOR, ENDOTHELIN A; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33846588433     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000247440.97569.fd     Document Type: Review

References (50)

1. Galiè N, Torbicki A, Barst RJ, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25:2243-2278.
2. Yuan J, Aldinger A, Juhaszova M, Wang J, Conte JV Jr, Gaine SP, et al. Dysfunctional voltage gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98:1400-1406.
3. Budhiraja R, Tudor R, Hasson P. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159-165.
4. Humbert M, Morrell N, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 suppl S):S13-S24.
5. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22:358-363.
6. Eisenberg P, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82:841-847.
7. Christman B, McPherson C, Newman J, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75.
8. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 suppl S):25S-32S.
9. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005; 112:553-562.
10. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasis. N Engl J Med 2001; 345:325-334.
11. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36:239-243.
12. Masuyama T, Kodama K, Kitabatake A, Sato H, Nanto S, Inoue M. Continuous-Wave Doppler echocardiographic detection of pulmonary regurgitation and its application to non invasive estimation of pulmonary artery pressure. Circulation 1986; 74:484-492.
13. Gorenflo M, Nelle M, Schnabel A, Ullmann MV. Pulmonary hypertension in infancy and childhood. Cardiol Young 2003; 13:219-227.
14. Mikkilineni S, Barst RJ, Cropp G. Pulmonary function in primary pulmonary hypertension. Pediatric Res 1990; 27:359a.
15. Barnes P, Liu S. Regulation of pulmonary vascular tone. Pharmacol Rev 1995; 47:87-131.
16. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73:372-382.
17. Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17:647-652.
18. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492.
19. Gorenflo M, Bettendorf M, Brockmeier K, Ulmer H. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. Z Kardiol 2000; 89:100-108.
20. Turanlahti M, Laitinen P, Sarna S, Pesonen E. Nitric oxide, oxygen and prostacyclin in children with pulmonary hypertension. Heart 1998; 79:169-174.
21. Gibbs JS, Higenbottam T. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86 (suppl 1): I1-I13.
22. Clabby ML, Canter CE, Moller JH, Bridges ND. Hemodynamic data and survival in children with pulmonary hypertension. J Am Coll Cardiol 1997; 30:554-560.
23. Atz A, Adatia I, Lock J, Wessel DI. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33:813-819.
24. Ichida F, Uese K, Tsubata S. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997; 80:662-664.
25. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy in primary pulmonary hypertension in children. Circulation 1999; 99:1197-1204.
26. Sitbon O, Humbert M, Jais X, et al. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension [Abstract]. Am J Resp Crit Care Med 2004; 169:A210.
27. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111.
28. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
29. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110:660-665.
30. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2:123-137.
31. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302.
32. Barst RJ, Maislin G, Fishman A. Vasodilatator therapy for primary pulmonary hypertension in children. Circulation 1999; 99:1197-1208.
33. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-bind placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496-1502.
34. Barst RJ, McGoon M, Mc Laughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125.
35. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347:322-329.
36. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Am J Respir Crit Care Med 2002; 165:800-804.
37. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
38. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:1380-1386.
39. Abrams D, Schulze-Neick I, Magee AG. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Heart 2000; 84:E4.
40. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43:1149-1153.
41. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:E5.
42. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22:547-560.
43. Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, Keck BM. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report. J Heart Lung Transplant 2002; 21:950-970.
44. Daliento L, Sommerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845-1855.
45. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865.
46. Stoica S, McNeil K, Perreas K, Sharples LD, Satchithananda DK, Tsui SS, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001; 72:1887-1891.
47. Clark RH, Kueser TJ, Marshall W, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342:469-474.
48. Dillon PW, Cilley RE, Mauger D, Zachary C, Meier A. The relationship of pulmonary artery pressure and survival in congenital diaphragmatic hernia. Pediatr Surg 2004; 39:307-312.
49. Egreteau L, Pauchard JY, Semama DS, Matis J, Liska A, Romeo B, et al. Chronic oxygen dependency in infants born at less than 32 weeks gestation: incidence and risk factors. Pediatrics 2001; 108:E26.
50. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 suppl S):25S-32S.